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Volume 6Available online 27 April 2021Background: Patient-reported outcomes (PROs) are increasingly relevant endpoints in clinical trials, contributing to our
understanding of riskebenefit profiles, in addition to efficacy and safety data.We investigated the impact of entrectinib
on patient-reported symptoms, functioning, and health-related quality of life.
Patients and methods: STARTRK-2 is a phase II basket study in patients with locally advanced/metastatic neurotrophic
receptor tyrosine kinase 1/2/3 (NTRK1/2/3) and ROS proto-oncogene 1 (ROS1) fusion-positive solid tumours. PROs
(prespecified secondary endpoint) were evaluated using the European Organization for Research and Treatment of
Cancer quality-of-life questionnaire (QLQ-C30), lung cancer module (QLQ-LC13), and colorectal cancer module (QLQ-
CR29), and the EuroQoL 5-Dimension 3-Level instruments, completed before cycle 1 day 1 and each subsequent 4-
week cycle of entrectinib dosing, and the end of treatment. Adverse events and treatment-related symptoms were
assessed in the safety analysis (SA)-PRO population. Tumour-related symptoms, functioning, and global health status
were assessed in the efficacy analysis (EA)-PRO population. Data cut-offs: 31 October 2018 NTRK cohort; 01 May
2019 ROS1 cohort.
Results: SA-PRO populations comprised patients with NTRK fusion-positive solid tumours (N ¼ 88) or ROS1 fusion-
positive non-small-cell lung cancer (N ¼ 180) who received one or more doses of entrectinib, completed PRO
questionnaires on cycle 1 day 1 and answered one or more questions on-study. EA-PRO populations (N ¼ 71) and
(N ¼ 145), respectively, comprised SA-PRO patients with measurable baseline disease. Moderate-to-high baseline
global health status scores were maintained in EA-PRO populations during treatment. Role and physical functioning
scores were moderate-to-high at baseline, with trends towards clinical improvement during treatment. Both cohorts
reported low-to-moderate symptom burden at baseline, which was maintained or trended towards clinically
meaningful improvement. Symptoms commonly associated with cancer treatment (e.g. nausea, fatigue) remained
stable or improved during treatment. All SA-PRO patients experienced one or more adverse events, most frequently
constipation or diarrhoea.
Conclusions: PRO findings were consistent with the favourable safety profile of entrectinib, and further reinforce the
positive benefiterisk profile of this treatment, indicating minimal overall treatment burden.
Key words: entrectinib, NTRK, patient-reported outcomes, ROS1, tyrosine kinase inhibitorondence to: Prof. Luis Paz-Ares, Medical Oncology Department, Hospital Universitario 12 de Octubre, Avenida de Córdoba SN, 28041 Madrid, Spain. Tel:
08-349
pazaresr@seom.org (L. Paz-Ares).
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Neurotrophic receptor tyrosine kinase (NTRK) and ROS
proto-oncogene 1 (ROS1) gene fusions are known onco-
genic drivers across a range of tumour types,1 which result
in constitutively active kinase activity.2,3 The European So-
ciety for Medical Oncology recommends NTRK testing in
advanced solid cancers and ROS1 testing in advanced non-
squamous non-small-cell lung cancer (NSCLC).4,5 Entrectinib
is an orally available, potent inhibitor of tropomyosin re-
ceptor kinase A/B/C, ROS1, and anaplastic lymphoma kinase
(ALK).6,7 In an integrated analysis of three clinical trials
(ALKA-372-001 [EudraCT, 2012e000148e88], STARTRK-1
[NCT2097810], and STARTRK-2 [NCT02568267]), entrecti-
nib demonstrated clinically meaningful efficacy for locally
advanced/metastatic NTRK fusion-positive solid tumours
[63.5% objective response rate (ORR), N ¼ 74] and ROS1
fusion-positive NSCLC (67.1% ORR, N ¼ 161), with a
manageable and favourable safety and tolerability profile.8,9
As a complement to traditional outcomes of efficacy and
tolerability, patient-reported outcomes (PROs) regarding
symptoms and their functional impact on daily activities
and health-related quality of life (HRQoL) are gaining
increasing recognition as important clinical trial end-
points.10 Appropriate consideration of PROs allows for a
more comprehensive assessment of an agent’s benefiterisk
profile by more fully integrating patients’ perspectives, and
ensuring treatment benefit is not outweighed by unac-
ceptable tolerability and reduced HRQoL.11 To provide in-
formation on the overall treatment burden associated with
entrectinib, we investigated the impact of treatment on
patient-reported symptoms, functioning, and HRQoL in the
STARTRK-2 study.
PROs were assessed using the core European Organisa-
tion for Research and Treatment of Cancer (EORTC) QoL
instrument (QLQ-C30),12 which is a widely used HRQoL
questionnaire that assesses global health status (GHS),
important functioning domains, and common cancer-
associated symptoms, as well as two additional supple-
ments, which were EORTC QLQ-LC13 (lung cancer
module)13 and EORTC QLQ-CR29 [colorectal cancer (CRC)
module].14 The International Consortium for Health Out-
comes Measurement has selected EORTC QLQ-C30, QLQ-
CR29, and QLQ-LC13 as standard tools for assessing PROs
as outcome indicators for patients with cancer, CRC, and
lung cancer, respectively.15MATERIALS AND METHODS
Patients and study design
The design of STARTRK-2, an open-label phase II basket
study, has been reported previously,8,9 and is outlined in
more detail in the Supplementary Appendix, available at
https://doi.org/10.1016/j.esmoop.2021.100113. Briefly, this
study included patients with locally advanced/metastatic
solid tumours harbouring an NTRK1/2/3, ROS1, or ALK gene
fusion who received oral entrectinib 600 mg once daily in2 https://doi.org/10.1016/j.esmoop.2021.1001134-week cycles. Patients with ALK fusion-positive solid tu-
mours were enrolled; however, this arm was discontinued
and therefore these data are not included in this analysis.Safety assessments
Safety was assessed by physical examination, laboratory
tests, monitoring of adverse events (AEs), and clinic visits.
AEs were coded using the Medical Dictionary for Regulatory
Activities (version 14.0 or higher for individual studies;
version 21.0 for the integrated safety analysis) and graded
using the National Cancer Institute Common Terminology
Criteria for Adverse Events (version 4.03).PRO assessments
PROs were prespecified secondary endpoints, evaluated in
all enrolled patients who completed questionnaires on
electronic devices before entrectinib dosing on day 1 of
every 4-week cycle starting at cycle 1, and at the end of
treatment. These included the EuroQoL Group 5-Dimension
3-Level version (EQ-5D-3L) (assesses health resource uti-
lisation; results not included in this publication) and QLQ-
C30, which includes 30 questions and comprises five
functional scales, three symptom scales, a GHS/QoL scale,
and six single items. The QLQ-LC13 module includes 13
questions assessing lung cancer-specific symptoms, while
the QLQ-CR29 module includes 29 questions assessing CRC-
specific symptoms (Supplementary Table S1, available at
https://doi.org/10.1016/j.esmoop.2021.100113).Statistical analysis
The safety analysis (SA) population included all enrolled
patients who received one or more doses of entrectinib. The
efficacy analysis (EA) population comprised all patients with
measurable baseline disease (by investigator) who received
one or more doses of entrectinib. The PRO populations
comprised all patients in the EA (EA-PRO population) or the
SA (SA-PRO population) populations who completed QLQ-
C30 on cycle 1 day 1 and answered one or more ques-
tions on an on-study time point thereafter. For NSCLC or
CRC baskets, the PRO populations included patients who
also completed QLQ-LC13 or QLQ-CR29, respectively, on
cycle 1 day 1 and answered one or more questions on an
on-study time point thereafter, in addition to QLQ-C30.
Analyses of QLQ-C30, QLQ-LC13, and QLQ-CR29 scores
were conducted in the EA-PRO population to assess com-
mon tumour-related symptoms, functioning, and GHS/QoL.
Analyses of QLQ-C30 treatment-related symptoms were
conducted in the SA-PRO population. The threshold for data
evaluation was 25% of the SA-PRO or EA-PRO populations
remaining enrolled and participating in the PRO question-
naires, in order to optimise the generalisability of the re-
sults. PRO data were summarised with descriptive statistics.
Select symptom scales (or single items if there is only one
item for that scale) were prespecified for analysis based onVolume 6 - Issue 3 - 2021
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evaluated.
PROs were scored according to the developers’ scoring
manual. All scales and single-item measures were linearly
transformed to a score range of 0-100. High scores on
functional/GHS scales represent a high level of functioning
and high HRQoL, respectively. Conversely, high symptom
scores represent greater symptomatology severity. PRO
scores are also presented here in comparison to EORTC
reference data from the general adult population and pa-
tients with NSCLC, as appropriate, to define low, moderate,
or high categorisation of scores.16 For multi-item subscales,
if 50% of items were missing at a time point, the multi-
item score was calculated on the basis of non-missing
items. If >50% of items were missing/a single-item mea-
sure was missing, the subscale was considered missing.
Interpreting scores was based on the subjective significance
questionnaire developed by Osoba et al.17 which assessed
patients’ perceptions of changes. Patients who reported ‘a
little’ change for better or worse on a particular scale had
QLQ-C30 changes ~5-10. Those reporting ‘moderate’ change
had changes ~10-20, and ‘very much’ corresponded to a
change >20. A 10-point change in a score was therefore
the threshold for clinical meaningfulness.17Ethical approval and consent to participate
The trial was conducted in accordance with Good Clinical
Practice guidelines and the provisions of the Declaration of
Helsinki. All patients provided written informed consent.
An independent data and safety monitoring committee
reviewed safety data regularly. Protocol approval was ob-
tained from an independent ethics committee at each site.RESULTS
Patients
Enrolment and data cut-offs were 30 April 2018 and 31
October 2018, respectively, for the NTRK fusion-positive
cohort and 31 October 2018 and 01 May 2019, respec-
tively, for the ROS1 fusion-positive cohort (STARTRK-2
enrolment ongoing at time of reporting). The SA-PRO pop-
ulation (N ¼ 268) comprised 88 patients with locally
advanced/metastatic NTRK fusion-positive solid tumours
and 180 patients with locally advanced/metastatic ROS1
fusion-positive NSCLC. The EA-PRO population (N ¼ 216)
comprised 71 patients with locally advanced/metastatic
NTRK fusion-positive solid tumours and 145 patients with
locally advanced/metastatic ROS1 fusion-positive NSCLC
(Supplementary Figure S1, available at https://doi.org/10.
1016/j.esmoop.2021.100113). Baseline patient characteris-
tics are summarised in Supplementary Tables S2 and S3,
available at https://doi.org/10.1016/j.esmoop.2021.100113.
A threshold of 25% of enrolled patients responding to the
questionnaire determined the number of cycles included in
subsequent analyses. Questionnaire completion rates,
which represent patients providing data amongst those
expected to complete the questionnaire at each time pointVolume 6 - Issue 3 - 2021(patients who had progressed were removed from the
denominator), were high at baseline for the ROS1 SA-PRO
and EA-PRO populations (97.8%-97.9%), and remained
high until the latest cycle included in analyses (cycle 18:
90.2%-90.7%). For the NTRK SA-PRO and EA-PRO pop-
ulations, baseline completion rates were high (85.7%-
100.0%) and decreased slightly by the latest cycle included
in analyses (cycle 12/13: 68.8%-80.0%).
Using normative scores of the EORTC from the general
adult population as a reference,16 patients in the NTRK and
ROS1 EA-PRO populations (N ¼ 88, N ¼ 145, respectively)
reported moderate-to-high QLQ-C30 GHS/QoL and func-
tioning at baseline, with slightly higher scores for the NTRK
EA-PRO population (baseline scores: GHS/QoL 68.6; physical
functioning 74.8; role functioning 66.9; cognitive func-
tioning 83.9) versus the ROS1 EA-PRO population (baseline
scores: GHS/QoL 56.0; physical functioning 71.5; role func-
tioning 62.4; cognitive functioning 82.8) (Table 1). Baseline
treatment-related symptom scores (QLQ-C30) and tumour-
related symptom scores (QLQ-LC13) were lower or com-
parable with normed scores for patients with NSCLC16
(Table 1).PROs in patients with NTRK fusion-positive solid tumours
Median treatment duration in the NTRK EA population (N ¼
71) was 8.5 months. According to the QLQ-C30, the EA-PRO
population maintained a high baseline GHS/QoL [68.6;
mean change from baseline range: þ5.3 to 4.4 (Table 1;
Figure 1A)] as well as a high baseline physical functioning
score (74.8; mean change from baseline: þ7.7 to 0.4)
during treatment (Table 1, Figure 2A). Notably, while there
was a moderate baseline role functioning score (66.9), this
reached a clinically meaningful improvement by cycle 10
day 1, which was maintained until cycle 13 day 1 [mean
change from baseline: þ12.3 (Table 1, Figure 2A)]. Cognitive
functioning was maintained at or just below the high
baseline level of 83.9 [mean change from baseline: þ0.8
to 7.6 (Table 1, Figure 2A)].
The NTRK NSCLC EA-PRO population (n ¼ 12) had a
median treatment duration of 7.9 months. Based on the
QLQ-LC13, a moderate-to-low baseline tumour-related
symptom burden was unchanged or improved throughout
treatment (Table 1). There was a low mean baseline score
for chest pain (5.6) that remained stable (one exception at
cycle 6 day 1: þ16.7 mean change from baseline), while
dyspnoea remained stable throughout, from a low baseline
mean score of 26.9. Cough had a moderate baseline mean
score (38.9) with clinically meaningful improvements in
symptom severity from cycle 3 day 1 (Figure 3A; mean
change from baseline: 14.8), which was maintained at
cycle 13 day 1 (mean change from baseline: 11.1). The
NTRK CRC EA-PRO population (n ¼ 6), had median treat-
ment duration of 4.2 months. Based on the QLQ-CR29, CRC-
associated symptom severity (n ¼ 7, including one patient
with neuroendocrine colon cancer) generally remained
unchanged or improved over time, in particular bloating,https://doi.org/10.1016/j.esmoop.2021.100113 3
Table 1. Mean baseline scores and mean change from baseline in global health status, functioning (based on QLQ-C30), and tumour-related symptom severity
(based on QLQ-LC13 and QLQ-CR29), in the NTRK EA-PRO population (N [ 71) and ROS1 EA-PRO population (N [ 145), and treatment-related symptom
severity (based on QLQ-C30) in the NTRK SA-PRO population (N [ 88) and ROS1 SA-PRO population (N [ 180)
QLQ-C30 functioning
scales
NTRK fusion-positive solid tumours ROS1 fusion-positive NSCLC

















GHS/QoL 68.6 þ5.3 þ5.3 to 4.4 56.0 þ4.1 þ11.3 to þ3.8
Physical functioning 74.8 þ6.3 þ7.7 to 0.4 71.5 þ5.7 þ8.8 to þ1.6
Role functioning 66.9 þ12.3 þ16.0 to 0.6 62.4 þ3.6 þ10.3 to 0.0





















Coughing 38.9 11.1 0.0 to 16.7 38.6 24.1 13.6 to 24.1
Chest pain 5.6 0.0 þ16.7 to 8.3 18.6 3.7 2.2 to 12.5
Dyspnoea 26.9 7.4 þ9.3 to 7.4 32.3 6.2 3.6 to 10.3
Arm/shoulder pain 27.8 22.2 5.6 to 25.9 18.6 5.6 2.3 to 11.6
Pain in other parts 33.3 þ11.1 þ16.7 to 18.5 24.9b 1.9c þ2.2 to 9.2
Peripheral neuropathy 13.9 0.0 þ22.2 to 0.0 14.1 0.0 þ8.7 to 0.0




NTRK CRC EA-PRO population (N ¼ 7)
BL score (n ¼ 6) Change from BL, C6a (n ¼ 2) Change from BL, range (C2e6a)
Abdominal pain 27.8 þ16.7 þ16.7 to 8.3
Bloating 33.3 þ50.0 þ50.0 to 16.7





















Fatigue 37.8 13.6 þ0.2 to 13.6 39.0 11.8 3.1 to 11.8
Nausea/vomiting 6.9 1.5 þ2.6 to 3.8 10.8 6.8 3.2 to 7.5
Insomnia 28.1 9.1 4.8 to 14.1 32.0 15.0 11.8 to 20.4
Appetite loss 21.1 18.2 10.0 to 18.2 28.0 15.7 14.3 to 22.2
Constipation 16.3 6.1 þ16.7 to 6.1 16.7 þ11.6 þ22.2 to þ8.3
Diarrhoea 8.9 þ13.6 þ13.6 to þ3.2 7.4 þ10.2 þ13.4 to þ6.1
All scores are mean or mean change from baseline. Scores range from 0 to 100. For functioning and GHS/QoL, higher score ¼ better HRQoL and function (improvement). For a
treatment-related or tumour-related symptom scale/item, however, lower score ¼ lower symptom severity (improvement). A 10-point change in score is the threshold for
clinical meaningfulness.
BL, baseline; C2, cycle 2 day 1; C6, cycle 6 day 1; C13, cycle 13 day 1; C18, cycle 18 day 1; CRC, colorectal cancer; EA, efficacy analysis; GHS, global health status; NSCLC, non-small-
cell lung cancer; NTRK, neurotrophic receptor tyrosine kinase; PRO, patient-reported outcomes; QoL, quality of life; ROS1, ROS proto-oncogene 1; SA, safety analysis.
a Cycle shown represents when 25% of the population (either the EA-PRO or SA-PRO) remained in the study.
b n ¼ 139.
c n ¼ 35.
ESMO Open L. Paz-Ares et al.blood/mucus in stool, buttock pain, dyspareunia, dysuria,
faecal incontinence, and flatulence (data not shown).
Patients in the NTRK SA-PRO population (N ¼ 88) re-
ported rapid and durable clinically meaningful improve-
ments in some QLQ-C30 treatment-related symptom scores,
where improvements exceeded the clinically meaningful
threshold at cycle 12 day 1 for both fatigue and appetite
loss. With the exception of diarrhoea, other key treatment-
related symptoms, including nausea, insomnia, and con-
stipation, remained stable (Table 1). Based on QLQ-C30 and
QLQ-LC13, in the NTRK SA-PRO population (N ¼ 88) the
high proportion of patients reporting treatment-related
symptoms ‘not at all’ in the past week remained stable or
increased for most symptoms, with no reports of ‘very
much’ for any symptom at cycle 12 day 1. The exception was4 https://doi.org/10.1016/j.esmoop.2021.100113a trend towards decreased reports in the ‘not at all’ cate-
gory and increased reports in the ‘a little’ category for
diarrhoea, constipation, and peripheral neuropathy
(Supplementary Table S4, available at https://doi.org/10.
1016/j.esmoop.2021.100113).PROs in patients with ROS1 fusion-positive NSCLC
Patients in the ROS1 EA population (N ¼ 145) had a median
treatment duration of 10.4 months. Based on the QLQ-C30,
the EA-PRO population maintained or improved both the
moderate baseline GHS/QoL score [56.0; mean change from
baseline range: þ11.3 to þ3.8 (Table 1, Figure 1B)] and
moderate baseline role functioning score (62.4; mean
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Figure 1. Mean change (with 95% CI) from baseline in global health status (left) and proportion of patients with clinically meaningful change in global health status
(right) based on QLQ-C30 in the EA-PRO population with (A) NTRK fusion-positive solid tumours (N ¼ 71) and (B) ROS1 fusion-positive NSCLC (N ¼ 145).
Scores range from 0 to 100. A high score for the GHS/QoL scale represents a high QoL. A 10-point change in score is the threshold for clinical meaningfulness. Only
visits with three or more patients are included.
C, cycle; CI, confidence interval; D, day; EA, efficacy analysis; GHS, global health status; NSCLC, non-small-cell lung cancer; NTRK, neurotrophic receptor tyrosine kinase;
PRO, patient-reported outcomes; QoL, quality of life; ROS1, ROS proto-oncogene 1.
L. Paz-Ares et al. ESMO Openfunctioning baseline score (71.5) was maintained at most
study visits, with a trend towards clinical improvement
(Table 1, Figure 2B). A high baseline cognitive functioning
score of 82.8 also remained stable throughout, with the
exception of cycle 14 [worst mean change score from
baseline: 10.8 at cycle 14 day 1 (Table 1, Figure 2B)].
According to the QLQ-LC13, the ROS1 EA-PRO population
(N ¼ 145) reported a low-to-moderate tumour-related
symptom burden which remained stable or improved
throughout. Coughing had a moderate baseline score (38.6),
with an immediate clinically meaningful marked improve-
ment (mean change in score from baseline: 13.6 at cycle 2
day 1), sustained throughout [mean change from
baseline: 24.1 at cycle 18 day 1 (Table 1, Figure 3B)]. A low
baseline chest pain score (18.6) improved or remained stable
throughout treatment, including an early clinically mean-
ingful improvement [mean change from baseline: 12.5 at
cycle 3 day 1, sustained until cycle 6 day 1: 10.6 (Table 1,
Figure 3B)]. Dyspnoea had a moderate baseline score, with aVolume 6 - Issue 3 - 2021consistent trend towards improvement during treatment,
while peripheral neuropathy and dysphagia had low baseline
scores, which remained stable with a trend towards wors-
ening in severity (Table 1).
Based on the QLQ-C30, the ROS1 SA-PRO population
(N ¼ 180) in general reported a stable or improved low-to-
moderate treatment-related symptom burden (Table 1).
Fatigue had a moderate baseline score of 39.0, which
remained stable with a trend towards improvement.
Appetite loss (baseline: 28.0) and insomnia (baseline: 32.0)
had immediate marked clinically meaningful improvements
(mean changes from baseline: 14.3 and 11.8, respec-
tively, at cycle 2 day 1), which were maintained at cycle 18
day 1 (mean changes from baseline: 15.7 and 15.0,
respectively). A low baseline nausea symptom score was
maintained during treatment. Constipation (baseline score:
16.7) demonstrated a sustained clinically meaningful wors-
ening over time, while the low baseline diarrhoea score
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Figure 2. Mean change from baseline in cognitive, physical, and role functioning scores based on QLQ-C30 in the EA-PRO population with (A) NTRK fusion-positive
solid tumours (N ¼ 71) and (B) ROS1 fusion-positive NSCLC (N ¼ 145).
Scores range from 0 to 100. A high score for functional scales represents a high/healthy level of functioning. A 10-point change in score is the threshold for clinical
meaningfulness. Only visits with three or more patients are included.
C, cycle; D, day; EA, efficacy analysis; NSCLC, non-small-cell lung cancer; NTRK, neurotrophic receptor tyrosine kinase; PRO, patient-reported outcomes; ROS1, ROS
proto-oncogene 1.
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Figure 3. Proportion of patients with clinically meaningful changes from baseline in selected tumour-related symptoms based on QLQ-LC13 in the EA-PRO
population with (A) NTRK fusion-positive NSCLC [coughing (left), pain in chest (right); N ¼ 12] and (B) ROS1 fusion-positive NSCLC [coughing (left), pain in
chest (right); N ¼ 145].
Scores range from 0 to 100. A high score for a tumour-related symptom scale/item represents a high level of symptomatology. A 10-point change in score is the
threshold for clinical meaningfulness. Only visits with three or more patients are included.
C, cycle; D, day; EA, efficacy analysis; NSCLC, non-small-cell lung cancer; NTRK, neurotrophic receptor tyrosine kinase; PRO, patient-reported outcomes; ROS1, ROS
proto-oncogene 1.
L. Paz-Ares et al. ESMO Openmeaningful symptom worsening until cycle 18 day 1
(Table 1). Based on QLQ-C30 and QLQ-LC13, in the ROS1 SA-
PRO population (N ¼ 180 and N ¼ 145, respectively), the
high proportion of patients at baseline reporting treatment-
related symptoms ‘not at all’ in the past week generally
remained stable, or increased by cycle 18 day 1 (including
appetite loss, nausea, vomiting, trouble sleeping, tingling
hands and feet, sore mouth). Reports remained stable or
decreased for ‘quite a bit’, and ‘very much’ at cycle 18 day 1
for these symptoms. The exceptions were constipation,
diarrhoea, and hair loss, which had decreased reports of
‘not at all’ by cycle 18 day 1 (Supplementary Table S4,
available at https://doi.org/10.1016/j.esmoop.2021.100113).Safety
All patients in the SA-PRO populations experienced at least
one AE; the most frequently reported AEs (any grade)Volume 6 - Issue 3 - 2021associated with QoL impairment were constipation (45.5%
of the NTRK SA-PRO population and 52.2% of the ROS1
SA-PRO population), diarrhoea (38.6% and 40.0%, respec-
tively), nausea (25.0% and 31.1%, respectively), and dysp-
noea (25.0% and 31.7%, respectively). Treatment-related
AEs leading to discontinuations occurred in 4.5% of the
NTRK SA-PRO population and 5.6% of the ROS1 SA-PRO
population. There were generally no notable differences
in the AE profile between the NTRK and ROS1 SA-PRO
populations (Table 2).DISCUSSION
Here we present PRO data from STARTRK-2, which provide
additional evidence to support the association of entrecti-
nib with clinically meaningful benefit in patients with NTRK
fusion-positive solid tumours or ROS1 fusion-positive
NSCLC.8,9 STARTRK-2 safety data demonstrate entrectinibhttps://doi.org/10.1016/j.esmoop.2021.100113 7
Table 2. Summary of safety in the NTRK and ROS1 SA-PRO population
Patients, n (%) NTRK fusion-positive
solid tumours (N ¼ 88)
ROS1 fusion-positive
NSCLC (N ¼ 180)
Median, months (range) 14.7 (0.1a-29.7) 16.8 (0.1a-37.8)
Patients with at least one
AE 88 (100.0) 180 (100.0)
Grade 3 AE 66 (75.0) 120 (66.7)
Serious AE 46 (52.3) 75 (41.7)
TRAEs grade 3 35 (39.8) 68 (37.8)
TRAEs leading to dose reduction 28 (31.8) 54 (30.0)
TRAEs leading to discontinuation 4 (4.5) 10 (5.6)
Study status at data cut-off
Ongoing/discontinued 49 (55.7)/39 (44.3) 108 (60.0)/72 (40.0)
Discontinuation due to death 33 (84.6) 50 (69.4)
Discontinuation due to consent withdrawal 5 (12.8) 18 (25.0)
Discontinuation due to loss to follow-up 1 (2.6) 2 (2.8)
Discontinued, other e 2 (2.8)
AEs associated with QoL impairment (any grade)
Constipation 40 (45.5) 94 (52.2)
Diarrhoea 34 (38.6) 72 (40.0)
Dyspnoea 22 (25.0) 57 (31.7)
Nausea 22 (25.0) 56 (31.1)
Vomiting 17 (19.3) 41 (22.8)
Decreased appetite 9 (10.2) 23 (12.8)
Dyspnoea exertional 2 (2.3) 3 (1.7)
AE, adverse event; NSCLC, non-small-cell lung cancer; NTRK, neurotrophic receptor tyrosine kinase; PRO, patient-reported outcomes; QoL, quality of life; SA, safety analysis; ROS1,
ROS proto-oncogene 1; TRAE, treatment-related AE.
a Censored.
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Overall, these PRO data support cumulative safety data, and
are consistent with the overall entrectinib benefiterisk
assessment. Importantly, patient-reported functioning and
HRQoL remained stable or showed a trend towards
improvement while on treatment. Patients with ROS1
fusion-positive NSCLC reported moderate-to-low treatment-
related and tumour-related symptom burdens throughout,
which remained stable or showed a trend towards
improvement in most categories, with clinically meaningful
improvements in lung-related symptom severity, in partic-
ular coughing, as well as some treatment-related symptoms
such as appetite loss and trouble sleeping. There were only
a few exceptions where there was a trend towards wors-
ening (peripheral neuropathy and dysphagia) or sustained
clinically meaningful worsening (constipation and diar-
rhoea). Patients with NTRK fusion-positive NSCLC or CRC
reported moderate-to-low treatment- and tumour-related
symptom burdens throughout, with either stable or clini-
cally meaningful improvements in key symptoms. High
questionnaire response rates indicate that the data are
representative of the overall trial population.
For this analysis, PRO symptoms for evaluation were
chosen based on the safety/efficacy profile of entrectinib,
which indicated that insomnia, appetite loss, nausea,
vomiting, constipation, diarrhoea, peripheral neuropathy,
and sore mouth were potentially bothersome. In both SA-
PRO populations, reports indicate no notable increase in
the severity of these symptoms during treatment. Results of
this analysis therefore demonstrate that these symptoms
had minimal impact on patients’ daily lives and HRQoL,
providing further support for the safety and tolerability of
entrectinib.8 https://doi.org/10.1016/j.esmoop.2021.100113Similar to QLQ-C30 and QLQ-C13 findings for a phase II
study of alectinib in patients with ALK fusion-positive
advanced NSCLC,18 entrectinib was associated with a
trend towards improvement in a number of lung cancer-
related symptoms, such as cough, dyspnoea, and chest
pain, a sustained high HRQoL, and PRO data were consistent
with previously reported safety data. The alectinib study
shows that a different tyrosine kinase inhibitor in a similar
patient population also demonstrates the capacity to
improve GHS/QoL and functioning, as well as alleviate the
tumour-related symptom burden, while contributing a
minimal treatment-related symptom burden. The value of
assessing PROs to generate a more informed benefiterisk
profile has also been demonstrated for other targeted
therapies. Crizotinib and lorlatinib study PRO assessments
demonstrated maintained or improved GHS, global QoL,
physical functioning and symptoms, e.g. fatigue, cough,
pain, and dyspnoea, but some worsening of specific
treatment-related symptoms.19,20
Safety findings demonstrate low discontinuation rates
due to treatment-related AEs. Rates of protocol-governed
dose reduction were similar in the NTRK and ROS1
SA-PRO populations (31.8% and 30.0%, respectively).
However, dose intensity was maintained throughout, with a
median dose intensity of 91.4% (NTRK EA population; N ¼
71) and 92.9% (ROS1 EA population; N ¼ 145), indicating
that for the majority of patients, dose modifications were
generally short term and did not result in a notable
decrease in entrectinib treatment received throughout the
study.
Strengths of this entrectinib PRO analysis include the use
of multiple validated questionnaires and the high comple-
tion rates, as well as alignment with entrectinib’s clinicalVolume 6 - Issue 3 - 2021
L. Paz-Ares et al. ESMO Opentrial efficacy and safety profile. However, some caution may
be needed when interpreting results due to the small
sample sizes. The single-arm STARTRK-2 trial design and lack
of blinding could also potentially create bias in self-
reporting, based on patients’ treatment expectations.
CONCLUSIONS
Entrectinib has a manageable and relatively favourable
safety and tolerability profile, which was similar for patients
with NTRK fusion-positive solid tumours or ROS1 fusion-
positive NSCLC. PRO findings are consistent with this pro-
file, and further reinforce the positive benefiterisk of this
treatment. In conclusion, from the patient’s perspective,
the overall treatment burden is minimal with entrectinib.
ACKNOWLEDGEMENTS
The authors thank the patients, their families, and the
participating study centres. Third-party medical writing
assistance, under the direction of the authors, was provided
by Alix Biancardi, of Ashfield MedComms, an Ashfield
Health company, and was funded by F. Hoffmann-La Roche
Ltd. GD acknowledges the support of the Ludwig Center at
Harvard and the Pan Mass Challenge (Paul’s Posse, Erica’s
Entourage, and the Sarcoma Cycling Brigade). The authors
acknowledge Thomas Karagiannis for contributions to the
PRO study design and analysis plan, and Elisabeth Piault-
Louis for her contributions to interpretation of the data.
FUNDING
This study was supported by F. Hoffmann-La Roche Ltd.
DISCLOSURE
LP-A or his relative has received consulting fees from
Genentech/F. Hoffmann-La Roche, Loxo Oncology, Bayer, Eli
Lilly, AstraZeneca, Pfizer, Merck Sharp & Dohme (MSD),
Novartis, Amgen, PharmaMar, Boehringer Ingelheim, Cel-
gene, Servier, Sysmex, Incyte, Ipsen, Adacap, Sanofi, and
Blueprint Medicines; sponsored research agreements from
Bristol-Myers Squibb (BMS), AstraZeneca, and MSD; travel/
accommodation expenses from Roche, AstraZeneca, MSD,
BMS, Pfizer, Takeda; serves on the board of Genómica; and
has a leadership role at the European Medicines Agency. LP-
A is co-founder and sits on the board of Altum sequencing.
FB has personal financial interests in AstraZeneca, Bayer,
BMS, Boehringer Ingelheim, Eli Lilly Oncology, F Hoffmann-
La Roche, Novartis, Merck, MSD, Pierre Fabre, Pfizer, and
Takeda; and institutional financial interests in AbbVie, ACEA,
Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim,
Eisai, Eli Lilly Oncology, F. Hoffmann-La Roche, Genentech,
Ipsen, Ignyta, Innate Pharma, Loxo, Novartis, Medimmune,
Merck, MSD, Pierre Fabre, Pfizer, Sanofi-Aventis, and
Takeda. SS is an advisory board member for Amgen, Bayer,
BMS, CheckMab, Celgene, Daiichi Sankyo, Incyte, Merck,
Novartis, F. Hoffmann-La Roche, and Seattle Genetics. M-JA
has received consultant fees and honoraria from AstraZe-
neca, Eli Lilly and Company, Takeda, F. Hoffmann-La Roche
Ltd, MSD, Merck, Boehringer Ingelheim, OnoVolume 6 - Issue 3 - 2021Pharmaceutical, BMS, and Alpha Pharmaceutical. AD has
received honoraria and consulting fees for advisory boards
from Ignyta/F. Hoffmann-La Roche/Genentech, Loxo/Bayer/
Eli Lilly, TP Therapeutics, AstraZeneca, Pfizer, Blueprint
Medicines, Takeda/Ariad/Millennium, Helsinn, BeiGene,
BerGenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences,
Verastem, MORE Health, AbbVie, 14ner/Elevation Oncology,
Remedica Ltd, ArcherDX, Monopteros, Novartis, EMD
Serono, Liberum, Repare RX, and Melendi; associated
research funding paid to institution by Pfizer, Exelixis, Taiho,
Teva, GlaxoSmithKline, and PharmaMar; research funding
from Foundation Medicine; royalties from Wolters Kluwer;
other from Merck, Puma, Merus, and Boehringer Ingelheim;
CME honoraria from Medscape, OncLive, PeerVoice, Physi-
cians Education Resources, Targeted Oncology, Research to
Practice, Axis, Peerview Institute, Paradigm Medical Com-
munications, WebMD, and MJH Life Sciences. AC received
consulting fees from Deciphera, Bayer, Genentech; received
research funding from F. Hoffmann-La Roche, Ignyta,
Bavarian Nordic, and Nant Pharma. CR is a speaker for MSD,
AstraZeneca; has research collaborations with Guardant
Health; is an advisory board member for Archer, Inivata,
EMD Serono, Novartis and BMS; has received non-financial
support from Guardant Health and research grant from
LCRF-Pfizer. JW is an advisory board member for Amgen,
AstraZeneca, Bayer, Blueprint, BMS, Boehringer Ingelheim,
Chugai, Daiichi Sankyo, Ignyta, Janssen, Eli Lilly, Loxo, MSD,
Novartis, Pfizer, F. Hoffmann-La Roche, Seattle Genetics,
and Takeda; and has conducted research projects sponsored
by MSD, Novartis, BMS, Janssen, and Pfizer. TS has received
research funding and honoraria from Astellas Pharma,
AstraZeneca, Chugai Pharmaceutical, Eli Lilly Japan, Kissei
Pharmaceutical, MSD, Nippon Boehringer Ingelheim,
Novartis Pharma, Pfizer Japan, Takeda Pharmaceutical;
honoraria from BMS, Kyowa Hakko Kirin, Nippon Kayaku,
Ono Pharmaceutical, Roche Singapore, Taiho Pharmaceu-
tical, Thermo Fisher Scientific, Yakult Honsha; and research
funding from Bayer Yakuhin, Daiichi Sankyo, Eisai, LOXO
Oncology, Merck Serono. RD reports advisory boards for: F.
Hoffmann-La Roche, Genentech, Bayer, Green Peptide,
Blueprint Medicines, Takeda, AstraZeneca and Rain Thera-
peutics; stock ownership, IP licensing fees and consulting
fees from Rain Therapeutics. Licensing fees for biological
materials from Genentech, Foundation Medicine, Black
Diamond, Pearl River, Voronoi, SeraCare, Ignyta, Loxo, Ariad,
GVKbio, and Chugai. AK, SM and SO report employment
with F. Hoffmann-La Roche/Genentech DC reports
employment with and equity in F. Hoffmann-La Roche. GD
received consulting fees from Novartis, Pfizer, EMD-Serono,
Sanofi Oncology, Janssen Oncology, Ignyta, Loxo Oncology,
Mirati Therapeutics, Epizyme, PharmaMar, Daiichi-Sankyo,
WIRB Copernicus Group, Ziopharm, and Polaris Pharma-
ceuticals; received research support to Dana-Farber from
Bayer, Novartis, Pfizer, Janssen Oncology, Ignyta, Loxo
Oncology, AbbVie, Epizyme, and Adaptimmune; patent
licensed to Novartis from Dana-Farber with royalty paid to
Dana-Farber; member, Board of Directors, Blueprint Medi-
cines and Merrimack Pharmaceuticals; member, Scientifichttps://doi.org/10.1016/j.esmoop.2021.100113 9
ESMO Open L. Paz-Ares et al.Advisory Board with consulting fees and equity, Blueprint
Medicines and Translate Bio; consultant, Scientific Advisory
Board with consulting fees and equity, G1 Therapeutics,
RELAY Therapeutics, CellCarta, Ikena Oncology, Caris Life
Sciences, and Champions Oncology; consultant with equity,
Bessor Pharmaceuticals. GD was supported in part by the
Ludwig Center at Harvard, the Dr Miriam and Sheldon
Adelson Medical Research Foundation, and the Pan Mass
Challenge (Paul’s Posse, Erica’s Entourage, and the Sarcoma
Cycling Brigade).DATA SHARING
Qualified researchers may request access to individual pa-
tient level data through the clinical study data request
platform (https://vivli.org/). Further details on Roche’s
criteria for eligible studies are available at https://vivli.org/
members/ourmembers/. For further details on Roche’s
Global Policy on the Sharing of Clinical Information and how




1. Liu D, Offin M, Harnicar S, Li BT, Alexander Drilon A. Entrectinib: an
orally available, selective tyrosine kinase inhibitor for the treatment of
NTRK, ROS1, and ALK fusion-positive solid tumors. Ther Clin Risk
Manag. 2018;14:1247-1252.
2. Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new
era of targeted therapy. Cancer Discov. 2015;5:25-34.
3. Davies KD, Doebele RC. Molecular pathways: ROS1 fusion proteins in
cancer. Clin Cancer Res. 2013;19:4040-4045.
4. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung
cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 2020;29:iv192-iv237.
5. Marchio C, Scaltriti M, Ladanyi M, et al. ESMO recommendations on
the standard methods to detect NTRK fusions in daily practice and
clinical research. Ann Oncol. 2019;30:1417-1427.
6. Menichincheri M, Ardini E, Magnaghi P, et al. Discovery of entrectinib:
a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK),
c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor ki-
nases (Pan-TRKs) inhibitor. J Med Chem. 2016;59:3392-3408.10 https://doi.org/10.1016/j.esmoop.2021.1001137. Ardini E, Menichincheri M, Banfi P, et al. Entrectinib, a pan-TRK, ROS1,
and ALK inhibitor with activity in multiple molecularly defined cancer
indications. Mol Cancer Ther. 2016;15:628-639.
8. Krebs MG, De Braud F, Siena S, et al. Efficacy and safety of entrectinib
in locally advanced/metastatic ROS1 fusion-positive NSCLC: an upda-
ted integrated analysis. Ann Oncol. 2020;31:S831-S833.
9. Rolfo C, De Braud F, Doebele RC, et al. Efficacy and safety of entrec-
tinib in patients with NTRK fusion-positive (NTRK-fp) solid tumors: an
updated integrated analysis. J Clin Oncol. 2020;38(15_Suppl): 3065-
3065.
10. Basch E. Patient-reported outcomes: an essential component of
oncology drug development and regulatory review. Lancet Oncol.
2018;19:595-597.
11. Zagadailov E, Fine M, Shields A. Patient-reported outcomes are
changing the landscape in oncology care: challenges and opportunities
for payers. Am Health Drug Benefits. 2013;6:264-274.
12. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organiza-
tion for Research and Treatment of Cancer QLQ-C30: a quality-of-life
instrument for use in international clinical trials in oncology. J Natl
Cancer Inst. 1993;85:365-376.
13. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The
EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality
of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials.
EORTC Study Group on Quality of Life. Eur J Cancer. 1994;30A:635-
642.
14. Gujral S, Conroy T, Fleissner C, et al. Assessing quality of life in patients
with colorectal cancer: an update of the EORTC quality of life ques-
tionnaire. Eur J Cancer. 2007;43:1564-1573.
15. ICHOM. International Consortium for Health Outcomes Measurement
(ICHOM). 2020. Available at: https://connect.ichom.org/standard-
sets/. Accessed January 22, 2021.
16. Scott NW, Fayers PM, Aaronson NK, et al. EORTC QLQ-C30 Reference
Values. Brussels, Belgium: EORTC Quality of Life Group; 2008.
17. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the sig-
nificance of changes in health-related quality-of-life scores. J Clin
Oncol. 1998;16:139-144.
18. Ou SI, Socinski MA, Gadgeel S, et al. Patient-reported outcomes in a
phase II, North American study of alectinib in patients with ALK-pos-
itive, crizotinib-resistant, non-small cell lung cancer. ESMO Open.
2018;3:e000364.
19. Blackhall F, Kim DW, Besse B, et al. Patient-reported outcomes and
quality of life in PROFILE 1007: a randomized trial of crizotinib
compared with chemotherapy in previously treated patients with ALK-
positive advanced non-small-cell lung cancer. J Thorac Oncol. 2014;9:
1625-1633.
20. Peters S, Shaw AT, Besse B, et al. Impact of lorlatinib on patient-re-
ported outcomes (PROs) in patients (pts) with advanced ALKþ or
ROS1þ non-small cell lung cancer (NSCLC). Ann Oncol. 2018;29:viii493-
viii547.Volume 6 - Issue 3 - 2021
